Current Studies

Currently enrolling subjects

 None at this time.

No longer enrolling, in long-term follow up

A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction (Pre-SERVE AMI), sponsored by Amorcyte.

Principal Investigator, Buddhadeb Dawn, MD

The primary objective of the study is to determine safety and the effect of intracoronary infusion of AMR-001 on myocardial perfusion using the resting total severity score (RTSS), measured by gated SPECT MPI at baseline and six months, in subjects with STEMI.

Single-center randomized double-blind placebo-controlled phase 2 proof of concept study to assess the efficacy and safety of ASCT01 in Patients with Critical Limb Ischemia, sponsored by Lifecells LLC.

Principal Investigator, Buddhadeb Dawn, MD

The primary objective of this trial is to compare the effects of treatment with ASCT01 with placebo in patients with critical limb ischemia who have exhausted all options for revascularization.

 Studies in start-up

Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an Anterior Myocardial Infarction and Ischemic Left Ventricular Dysfunction (ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration, ALLSTAR), sponsored by Capricor.

Principal Investigator, Buddhadeb Dawn, MD

The purpose of this study is to determine the safety profile of CAP-1002 administered by intracoronary infusion in patients with ischemic left ventricular dysfunction and a previous anterior myocardial infarction (MI).

Enrollment is expected to begin Feb-March 2014

Last modified: Apr 23, 2015
I want to...

Learn more about Adult Stem Cells

Learn more about the 2015 Conference

Donate to MSCTC

Contact MSCTC